What changed
2026-08-11 13:18 UTC → 2026-09-01 13:44 UTC ·
added
removed
The Oxford Vaccine Group’s Phase 1 safety and immunogenicity study of ChAdOx1 BDBV began in late July 2026 Clinical efforts to address the Bundibugyo Ebola outbreak in the United Kingdom, enrolling Democratic Republic of the Congo (DRC) continue to expand. The outbreak, which has seen infections surpass 4,000 cases, has prompted the WHO and Africa CDC to declare a healthy British volunteer. public-health emergency of international concern. In Canada, Moderna’s mRNA-1469 vaccine entered a parallel Phase 1 trial in Canada, with Health Canada authorising the study for its mRNA-1469 vaccine began on 30 July and 3 August, with the first participant dosed on 3 August at the in Truro, Nova Scotia site; enrolment will cover about 80 healthy adults across Truro, Scotia. The study, which includes sites in Halifax and Toronto. CEPI has pledged up Toronto, aims to US $50 million enroll approximately 80 healthy adults to support pre-clinical work, the Phase 1 study assess safety and manufacturing. Both companies have immune response. Moderna has committed to supply providing at least 500,000 doses to low- and middle-income countries at access-pricing if licensed. The trials respond to a worsening Bundibugyo Ebola outbreak in the Democratic Republic of the Congo, which has seen infections surpass 4,000 cases. The WHO and Africa CDC have declared a public-health emergency of international concern. In the DRC, NanoViricides has received regulatory approval from the Congolese Pharmaceutical Regulatory Authority (ACOREP) to begin Phase 2 trials for its NV-387 treatment, which will utilize utilizes an oral solid formulation in gummy formulation. Furthering vaccine development, the form of gummies. While experts note Coalition for Epidemic Preparedness Innovations (CEPI) has pledged up to $16.5 million to the African biopharmaceutical company Minapharm Group. This funding will support a vaccine candidate designed by ProBioGen that utilizes the MVA-CR19 modified vaccinia Ankara platform. This candidate is the fifth Bundibugyo-specific vaccine supported by CEPI and is designed to induce both B- and T-cell responses to aim for long-lasting immunity. While existing vaccines targeting for the Zaire strain may offer some cross-protection, the Bundibugyo strain is considered remains rare and currently lacks approved vaccines or specific treatments.